Nalaganje...
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
Heart failure is frequently associated with diabetes, and therapies which reduce mortality in people with heart failure and reduced ejection fraction (HFrEF) are often limited to drugs which modulate the renin–angiotensin–aldosterone system or heart rate control and occasionally to device therapy. T...
Shranjeno v:
| izdano v: | Diabetes Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7434820/ https://ncbi.nlm.nih.gov/pubmed/32710261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00889-9 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|